Somaxon’s Silenor Joins Sleep Aid Market
According to Richard Pascoe, president and CEO of Somaxon, Silenor the first sleep aid that hasn’t been deemed a controlled substance.
insomnia
Purdue, Transcept Sign $145M Deal for Sleep Aid
Purdue Pharmaceutical Products and Transcept Pharmaceuticals have signed a $145 million agreement to commercialize the sleep aid Intermezzo in the U.S.